US Generic Injectable Market Size, Demand, Share, Growth Drivers, Companies and Forecast 2023-2028
IMARC Group has recently released a new research study titled “US Generic Injectables Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028”, offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends and competitive landscape to understand the current and future market scenarios.
How big is the US generic injectables market?
The US generic injectables market size reached US$ 18.1 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 32.7 Billion by 2028, exhibiting a growth rate (CAGR) of 9.8% during 2023-2028.
 |
| US Generic Injectable Market Report | IMARC Group |
Industry Overview:
A generic injectable is a bioequivalent version of a branded injectable medication, typically offered at a lower cost. These injectables contain the same active ingredients, potency, and dosage form as their branded counterparts, but they may differ in inactive ingredients such as preservatives or stabilizers. Generic injectables undergo rigorous testing and evaluation by regulatory agencies to ensure their safety, efficacy, and quality. They are commonly used in various medical settings, including hospitals, clinics, and home healthcare, for a wide range of treatments such as pain management, anti-infectives, anesthesia, and cardiovascular care.
Request to Get the Sample Report: https://www.imarcgroup.com/us-generic-injectables-market/requestsample
US Generic Injectables Market Demand, Trends and Growth Drivers:
The cost advantage that generic injectables offer over branded equivalents, represents one of the key factors driving the growth of the market across the United States. This helps to manage healthcare expenditures effectively which is influencing the market growth.
The market is also driven by the increasing elderly population in the U.S. requires various medications for chronic conditions, thus fueling demand for more affordable healthcare solutions like generic injectables. Insurance companies often encourage the use of generic versions to lower the cost of medical treatments, which promotes market growth. The U.S. FDA is streamlining approval processes for generic injectables, which is facilitating quicker market entry and thereby encouraging competition.
Generic injectables often fill gaps created by shortages in branded medications, which is sustaining the market growth. The wide applicability of injectables in diverse therapeutic areas, such as pain management, oncology, and anti-infectives, is contributing to sustained demand. The expiry of patents on branded injectables opens the door for generic versions, providing new market opportunities.
Innovations in drug formulation and delivery technologies are also helping improve the stability and efficacy of generic injectables. The increasing awareness among consumers about the efficacy and cost advantages of generic drugs, supported by educational campaigns, is also fueling the market growth.
What Is Included In Market Segmentation?
The report has segmented the market into the following categorie
Breakup by Therapeutic Area:
- Oncology
- Anesthesia
- Anti-Infectives
- Parenteral Nutrition
- Cardiovascular
Breakup by Container:
- Vials
- Ampoules
- Premix
- Prefilled Syringes
Breakup by Distribution Channel:
- Hospitals
- Retail Pharmacy
Breakup by Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Competitive Landscape with Key Players:
Generic Injectable Companies in US:
- Hospira (Pfizer Inc.)
- Hikma Pharmaceuticals PLC
- Fresenius Kabi AG
- Sagent Pharmaceuticals, Inc
- Sandoz (Novartis).
- Henry Shein Inc.
Speak to Analyst: https://www.imarcgroup.com/request?type=report&id=816&flag=C
Key Highlights of the Report:
- Market Performance (2017-2022)
- Market Outlook (2023-2028)
- Market Trends
- Market Drivers and Success Factors
- Impact of COVID-19
- Value Chain Analysis
- Comprehensive mapping of the competitive landscape
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Media Contact:
Company Name: IMARC Group
Contact Person: Elena Anderson
Email: sales@imarcgroup.com
Phone: +1-631-791-1145
Address: 134 N 4th St
City: Brooklyn
State: NY
Country: United States
Website: https://www.imarcgroup.com
